Literature DB >> 32246503

SARS-COV-2 and infectivity: Possible increase in infectivity associated to integrin motif expression.

Ilaria Tresoldi1, Carla F Sangiuolo2, Vittorio Manzari1, Andrea Modesti1.   

Abstract

Entities:  

Keywords:  coronavirus; pandemics; receptor binding

Mesh:

Substances:

Year:  2020        PMID: 32246503      PMCID: PMC7228266          DOI: 10.1002/jmv.25831

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
To the Editor, Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) represents the causal agent of a potentially fatal disease (coronavirus disease 2019) that is actually of great global public health concern. SARS‐COV‐2 has diffused throughout the world surprisingly fast demonstrating a far greater infectivity than previously known human coronaviruses and it is also responsible for an unusual high variety of symptoms in affected patients. Since viruses need to penetrate cells to replicate, one of their most important characteristics is the ability to interact with the cell membrane. Different viruses utilize different approaches to penetrate into the cell, but they all use cell receptors through a method that mimics the receptor's ligand binding. The virus transmission efficiency is directly correlated to the affinity of the virus to its cell membrane receptor. The presence of different receptors for the same virus on different cell types has been demonstrated, but even on the same cell, there can be different kind of receptors for the same virus. It has been proposed that SARS‐COV‐2 has acquired the spike glycoprotein RGD (KGD in SARS‐CoV) integrin‐binding site which is considered significant for the virus transmission efficiency. The sequence arginine‐glycine‐aspartic acid (RGD) was identified as a general integrin‐binding motif, but individual integrins are also specific for particular protein ligands. The most common of these motifs is the minimal peptide sequence for binding integrins, RGD, which is known for its role in virus infection via its ability to interact with over half of the more than 20 known integrins. , However, not all virus‐integrin interactions are RGD‐dependent. Non‐RGD binding integrins have also been shown to effectively promote virus entry and infection. This type of virus‐integrin binding is shown to facilitate adhesion, cytoskeleton rearrangement, integrin activation, and increased intracellular signaling. The tripeptide LDI is also present in the spike glycoprotein SARS‐COV‐2. SARS‐CoV‐2 554 TLEILDIT 633 SARS‐ CoV 540 TSEILDIS 619 BAT‐Cov 563 TLEILDIT 642 Integrins are a family of cell surface receptors, formed through a noncovalent association of two type I transmembrane glycoproteins, the 18‐α and 8‐β subunits, which combine to form at least 24 different heterodimers to mediate the attachment of cells to the extracellular matrix as well to other cells. Integrins are widely expressed and every nucleated cell in the body owns a specific integrin signature. Of note, the regulation of integrins is dynamic and quickly changes once cells are taken out of their normal environment. Integrins interaction with their extracellular ligands is tunable by microenvironment signals, such as chemokines and growth factors. It has been demonstrated that this kind of interaction is strictly correlated to the progression of many diseases such as tumors and chronic inflammatory disorders. A few integrins are more restricted than others to certain cell lineages, but the expression is often developmentally regulated. Integrins were also found to be overexpressed on the surface of several inflamed tissues. Besides the fibronectin binding motif RGD, other integrin‐binding sites are specifically expressed in SARS‐COV‐2, and, particularly, a change from a LDV to a LDI motif is likely significant. The LDV/LDI switch in human immunodeficiency virus infection has been shown to play a key role in strain diffusion, contributing to high viral infectivity. We investigated the protein sequence of the human coronavirus and compared it to SARS and bat coronavirus to identify any eventual overexpression of other integrin‐binding sites. As expected, many integrin‐binding motifs were conserved on the three sequences, but others were differently distributed. Interestingly, binding sequences of the SARS‐COV‐2 seems to be more similar to bat virus than SARS‐Cov virus. Orf1ab polyprotein has many integrin‐binding motifs implicated in cell adhesion with binding sites on Fibronectin, Tenascin_C, and VCAM. This polyprotein has RGD (KRGDK), LDI, LDV, LDG, LDS, LET, KTS, IDG homologous sequences LDV and IDA, LDA and IDS, all these serving as ligand binding sites for alpha/beta subfamilies of integrin. , , , SARS‐CoV‐2 LIQPIGALDISASIVA 3034 SARS‐CoV LVQPVGALDVSASVVA 3011 BAT‐Cov LIQPIGALDISASIVA 3033 On the basis of these preliminary observations, we agree on the importance of focusing research studies on integrin‐binding sites and their correlation with viral transmission efficiency. The interaction of integrins with their ligands or their expression in different tissues and cells may be considered as potential therapeutic targets. These class of therapeutic agents has already been developed for the treatment of oncologic and chronic inflammatory diseases making possible treatments readily available if proven effective. Of additional interest is the use of molecules able to interfere with cytokines production, as these biomolecules are responsible for the modulation of integrin expression. , , , , , Our conclusion is that further investigation into any possible links between integrin‐binding peptides and their correlation with coronavirus infectivity and diffusion are needed, especially considering that their possible inhibition could be a potential therapeutic target for the SARS‐COV‐2 infection.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

IT, VM, and AM contributed equally to this paper. CFS contributed in sequence analysis.
  15 in total

Review 1.  Therapeutic antagonists and conformational regulation of integrin function.

Authors:  Motomu Shimaoka; Timothy A Springer
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

2.  Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics.

Authors:  Tsan Xiao; Junichi Takagi; Barry S Coller; Jia-Huai Wang; Timothy A Springer
Journal:  Nature       Date:  2004-09-19       Impact factor: 49.962

Review 3.  RGD and other recognition sequences for integrins.

Authors:  E Ruoslahti
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

Review 4.  α4β7 integrin inhibitors: a patent review.

Authors:  Hao Li; Shi-Ying Huang; Fang-Hong Shi; Zhi-Chun Gu; Shun-Guo Zhang; Ji-Fu Wei
Journal:  Expert Opin Ther Pat       Date:  2018-11-22       Impact factor: 6.674

Review 5.  Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

Authors:  Paul O'Connor
Journal:  Expert Opin Biol Ther       Date:  2007-01       Impact factor: 4.388

6.  Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin.

Authors:  X Z Huang; J F Wu; D Cass; D J Erle; D Corry; S G Young; R V Farese; D Sheppard
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

7.  A potential role for integrins in host cell entry by SARS-CoV-2.

Authors:  Christian Ja Sigrist; Alan Bridge; Philippe Le Mercier
Journal:  Antiviral Res       Date:  2020-03-01       Impact factor: 5.970

Review 8.  Integrins.

Authors:  Malgorzata Barczyk; Sergio Carracedo; Donald Gullberg
Journal:  Cell Tissue Res       Date:  2009-08-20       Impact factor: 5.249

Review 9.  The integrins.

Authors:  Yoshikazu Takada; Xiaojing Ye; Scott Simon
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 10.  Charomers-Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery.

Authors:  Ulrich Hahn
Journal:  Int J Mol Sci       Date:  2017-12-06       Impact factor: 5.923

View more
  11 in total

1.  Integrins as Therapeutic Targets for SARS-CoV-2.

Authors:  Timothy E Gressett; Danielle Nader; Juan Pablo Robles; Tione Buranda; Steven W Kerrigan; Gregory Bix
Journal:  Front Cell Infect Microbiol       Date:  2022-04-29       Impact factor: 6.073

2.  Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host factors having implication in the disease pathogenesis and severity.

Authors:  Voddu Suresh; Varshasnata Mohanty; Kiran Avula; Arup Ghosh; Bharati Singh; Rajendra Kumar Reddy; Deepti Parida; Amol Ratnakar Suryawanshi; Sunil Kumar Raghav; Soma Chattopadhyay; Punit Prasad; Rajeeb Kumar Swain; Rupesh Dash; Ajay Parida; Gulam Hussain Syed; Shantibhusan Senapati
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

3.  New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection.

Authors:  Shijia Yan; Haixia Sun; Xianzhang Bu; Guohui Wan
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

4.  Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2.

Authors:  Abul Bashar Mir Md Khademul Islam; Md Abdullah-Al-Kamran Khan; Rasel Ahmed; Md Sabbir Hossain; Shah Md Tamim Kabir; Md Shahidul Islam; A M A M Zonaed Siddiki
Journal:  J Transl Med       Date:  2021-01-07       Impact factor: 5.531

5.  The Spike Glycoprotein of SARS-CoV-2 Binds to β1 Integrins Expressed on the Surface of Lung Epithelial Cells.

Authors:  Eun Jeong Park; Phyoe Kyawe Myint; Michael Gyasi Appiah; Samuel Darkwah; Siqingaowa Caidengbate; Atsushi Ito; Eri Matsuo; Eiji Kawamoto; Arong Gaowa; Motomu Shimaoka
Journal:  Viruses       Date:  2021-04-09       Impact factor: 5.048

6.  Can the SARS-CoV-2 Spike Protein Bind Integrins Independent of the RGD Sequence?

Authors:  Christopher A Beaudoin; Samir W Hamaia; Christopher L-H Huang; Tom L Blundell; Antony P Jackson
Journal:  Front Cell Infect Microbiol       Date:  2021-11-18       Impact factor: 5.293

Review 7.  Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.

Authors:  Catharina Korsukewitz; Stephen W Reddel; Amit Bar-Or; Heinz Wiendl
Journal:  Nat Rev Neurol       Date:  2020-07-08       Impact factor: 44.711

8.  The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.

Authors:  Brandon J Beddingfield; Naoki Iwanaga; Prem P Chapagain; Wenshu Zheng; Chad J Roy; Tony Y Hu; Jay K Kolls; Gregory J Bix
Journal:  JACC Basic Transl Sci       Date:  2020-10-16

Review 9.  Recent advances in antibody-based immunotherapy strategies for COVID-19.

Authors:  Abdolreza Esmaeilzadeh; Samaneh Rostami; Pegah M Yeganeh; Safa Tahmasebi; Majid Ahmadi
Journal:  J Cell Biochem       Date:  2021-06-23       Impact factor: 4.480

10.  COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission.

Authors:  Pietro Sollena; Simone Cappilli; Alfredo Piccerillo; Andrea Chiricozzi; Ketty Peris
Journal:  Int J Dermatol       Date:  2020-09-24       Impact factor: 3.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.